ArticleBriefings in bioinformatics2026
BiChemoCLAM: a weakly supervised multimodal framework for chemotherapy response prediction.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Supervised fine-tuning enhances unsupervised learning from 45 million amino acids in TCR and peptide sequences.Bioinformatics (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chemotherapy is an important treatment for cancer patients, but it comes with risks. Therefore, effective chemotherapy response prediction is crucial. While whole slide image provides high-resolution insights into tumour environments, existing weakly supervised learning frameworks struggle to effectively integrate molecular data, such as gene expression, limiting their predictive power in complex chemotherapy response and small-sample scenarios. We present a bimodal chemotherapy response multi-instance learning framework, BiChemoCLAM, a novel multimodal deep learning framework that combines attention-driven multiple instance learning with multimodal compact bilinear pooling for interpretable and data-efficient chemotherapy response prediction. It achieves an Area Under Curve (AUC) of 80.91%, 71.68%, and 75.80% on ovarian serous cystadenocarcinoma, colorectal adenocarcinoma, and bladder urothelial carcinoma cancer datasets, respectively. The experimental results show that BiChemoCLAM is an effective model for predicting response to chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.